Accessibility Menu
Nuformix Plc logo

Nuformix Plc(LSE) NFX

Current Price£0.00
Market Cap£4.14MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)-96%
5 Year-89%
1 Year+102%
1 Month-8%
Nuformix Plc last closing stock price
MetricPriceDate
Last closeGBX 0.182026-07-23
Nuformix Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+3.82%GBX 0.172026-07-16
1 month-7.83%GBX 0.192026-06-23
3 month-1.94%GBX 0.182026-04-24
Year to date-30.78%GBX 0.262025-12-31
1 year+101.71%GBX 0.092025-07-23
3 year-32.89%GBX 0.262023-07-24
5 year-89.46%GBX 1.682021-07-23
Since inception-95.7%GBX 0.042017-10-16

Nuformix Plc Financials at a Glance

Market Cap

£4.14MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

£0.00

Net Income (TTM)

-£4.64M

EPS (TTM)

-£0.00

P/E Ratio

-5.28

Dividend

£0.00

Beta (Volatility)

0.12 (Low)

Price

£0.00

Volume

7,984,361

Open

£0.00

Previous Close

£0.00

Daily Range

£0.00 - £0.00

52-Week Range

£0.00 - £0.01

Estimated Earnings Date

May 28, 2026

NFX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Nuformix Plc

Nuformix plc is a UK-based pharmaceutical company focused on developing innovative therapies for fibrotic diseases and cancer through drug repurposing. The company is advancing several promising candidates in its portfolio, including NXP001, NXP004, and NXP002.

Products and Services
  • NXP001: Advanced beyond Phase 1 trials for oncology supportive care
  • NXP004: A novel variant of Olaparib in intellectual property generation stage
  • NXP002: Undergoing pre-clinical evaluation for idiopathic pulmonary fibrosis
Growth Outlook
  • Strong focus on drug repurposing may reduce development costs and time
  • Potential market for fibrotic diseases and cancer therapies is expanding
  • Partnership with Oxilio Ltd. enhances development capabilities for NXP001
Financial Highlights
  • Recent quarterly net income of -£346,577 indicates ongoing investment in R&D
  • Cash and cash equivalents of £930,283 provide operational runway
  • TTM price-to-earnings ratio of 5.74 suggests potential undervaluation
Nuformix plc operates in the biotechnology sector, leveraging its expertise in drug repurposing to address significant unmet medical needs. The company's current development pipeline includes several candidates that target critical health issues, particularly in oncology and fibrotic diseases. The strategic focus on repurposing existing drugs may lead to faster and more cost-effective solutions, appealing to both investors and healthcare providers. The growth outlook for Nuformix is promising, driven by an expanding market for therapies targeting fibrotic diseases and cancer. The partnership with Oxilio Ltd. is a strategic move that may enhance the development of NXP001, potentially accelerating its path to market. Financially, the company is in a phase of investment, as indicated by the recent quarterly net loss. However, the available cash reserves provide a solid foundation for ongoing operations and research activities. The low price-to-earnings ratio suggests that the stock may be undervalued, presenting an opportunity for potential investors to consider the long-term growth prospects of Nuformix plc.
AI Generated • Jun 30, 2026

Industry

Pharmaceuticals

Sector

Health Care

CEO

Anne Brindley, PhD

Website

www.nuformix.com

Headquarters

London, GL EC3V 0HR, GB

NFX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-83.53%

Return on Capital

-87.50%

Return on Assets

-53.59%

Earnings Yield

-18.94%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

£4.14MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

2.61B

Volume

7.98M

Avg. Volume

21.91M

Financials (TTM)

Gross Profit

-£49.29K

Operating Income

-£4.65M

EBITDA

-£1.46M

Operating Cash Flow

-£951.02K

Capital Expenditure

£0.00

Free Cash Flow

-£951.02K

Cash & ST Invst.

£930.28K

Total Debt

£0.00

Nuformix Plc Performance Analysis

Nuformix Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31GBP 0N/A
20232023-09-30GBP 0N/A
20242024-09-30GBP 0N/A
20252025-09-30GBP 0N/A
Nuformix Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-09-30N/A
Q22025-03-31N/A
Q42025-09-30N/A
Q22026-03-31N/A
Nuformix Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31GBP -0.00-38.9%
20232023-09-30GBP -0.00-38.9%
20242024-09-30GBP -0.00275.0%
20252025-09-30GBP -0.00-91.1%
Nuformix Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-09-30N/A
Q22025-03-31N/A
Q42025-09-30N/A
Q22026-03-31N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

£0.00

N/A

Gross Profit

£0.00

+100.0%

Gross Margin

0.00%

N/A

Market Cap

£4.14MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

£1.38M

N/A

Employees

3

N/A

Net Income

-£346.58K

-142801.3%

EBITDA

-£332.26K

-141879.4%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

£930.28K

+406.9%

Total Debt

£0.00

N/A

Accounts Receivable

£50.58K

-48.6%

Inventory

£0.00

N/A

Long Term Debt

£0.00

N/A

Short Term Debt

£0.00

N/A

Return on Assets

-53.59%

N/A

Return on Invested Capital

-61.52%

N/A

Free Cash Flow

-£395.35K

-234428.9%

Operating Cash Flow

-£395.35K

-234427.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TCF.LTheracryf Plc
£0.00-3.57%
TRX.LTissue Regenix Group plc
£0.07+0.00%
OBD.LOxford BioDynamics Plc
£0.00-15.38%
FUM.LFutura Medical plc
£0.00-7.69%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$10.96-0.02%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$40.94+0.02%
TQQQProShares Trust - ProShares UltraPro Qqq
$70.28-0.02%
NOKNokia
$10.30-0.03%

Questions About NFX

What is the current price of Nuformix Plc?

Nuformix Plc is trading at £0.00 per share.

What is the 52-week range for Nuformix Plc?

Over the past 52 weeks, Nuformix Plc has traded between £0.00 and £0.01.

How much debt does Nuformix Plc have?

As of the most recent reporting period, Nuformix Plc reported total debt of £0.00.

How much cash does Nuformix Plc have on hand?

Nuformix Plc reported £97.55K in cash and cash equivalents in its most recent financial results.

What is Nuformix Plc’s dividend yield?

Nuformix Plc does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services